{
    "nctId": "NCT01013506",
    "briefTitle": "Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Time to progression",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast carcinoma\n\n  * Stage IV disease\n* No locally recurrent resectable disease\n* No symptomatic brain metastases\n\n  * History of brain metastases allowed provided the patient is clinically stable for \\> 3 weeks after completion of radiotherapy AND is not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers\n* Hormone receptor status:\n\n  * Estrogen receptor and/or progesterone receptor positive tumor by immunohistochemistry (IHC)\n\nPATIENT CHARACTERISTICS:\n\n* Pre- or post-menopausal\n* ECOG performance status 0-1\n* Life expectancy \u2265 6 months\n* ANC \u2265 1,250/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN (\u2264 3 times ULN if liver metastasis is present)\n\n  * For patients with Gilbert syndrome, direct bilirubin will be measured instead of total bilirubin\n* SGOT and SGPT \u2264 1.5 times ULN (\u2264 3 times ULN if liver metastasis is present)\n* Alkaline phosphatase \u2264 1.5 times ULN (\u2264 3 times ULN if liver metastasis is present)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception during and for 3 months after completion of study therapy\n* Able to swallow and retain oral medication\n* Baseline QTc \u2264 450 msec\n* No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell skin cancer or successfully treated cervical carcinoma in situ\n* No malabsorption syndrome significantly affecting gastrointestinal function\n* No diabetes, fasting glucose \\> 150mg/dL, or receiving ongoing anti-hyperglycemic therapies\n* No concurrent uncontrolled illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection requiring parenteral antibiotics\n  * Impaired lung function (i.e., COPD or lung conditions requiring oxygen therapy)\n  * Symptomatic congestive heart failure (NYHA class III or IV heart disease)\n  * Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months\n  * Uncontrolled hypertension, defined as systolic BP \\> 180 mm Hg or diastolic BP \\> 100 mm Hg on two consecutive measurements taken \u2265 1 week apart, despite adequate medical support\n  * Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, or ventricular tachycardia that is symptomatic or requires treatment)\n  * Psychiatric illness and/or social situation that would compromise patient safety or limit compliance with study requirements, including maintenance of a compliance/pill diary\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from prior therapy\n* At least 2 weeks since prior investigational drugs\n* No more than 4 prior chemotherapy treatments in the metastatic setting\n\n  * Does not include endocrine therapy or single-agent biologic therapy\n* No concurrent CYP3A4 or CYP1A2 modifiers\n* No other concurrent anticancer therapy, including chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biologic therapy\n\n  * Concurrent radiotherapy to painful bone metastases or areas of impeding bone fracture allowed provided radiotherapy is initiated before study therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}